Brown Brothers Harriman & Co. Has $92,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Brown Brothers Harriman & Co. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 468.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 466 shares of the medical research company’s stock after purchasing an additional 384 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in IQVIA were worth $92,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Intech Investment Management LLC acquired a new stake in shares of IQVIA in the third quarter worth about $223,000. Captrust Financial Advisors lifted its holdings in IQVIA by 30.8% in the 3rd quarter. Captrust Financial Advisors now owns 8,188 shares of the medical research company’s stock worth $1,940,000 after purchasing an additional 1,927 shares during the last quarter. PDT Partners LLC bought a new stake in IQVIA during the third quarter worth approximately $853,000. Point72 Hong Kong Ltd acquired a new position in IQVIA during the third quarter valued at approximately $434,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of IQVIA in the third quarter valued at approximately $504,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IQV. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Barclays cut their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Finally, JPMorgan Chase & Co. cut their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 2.9 %

IQV stock opened at $171.11 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $30.17 billion, a P/E ratio of 22.81, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1-year low of $169.37 and a 1-year high of $252.88. The business’s 50 day moving average is $192.05 and its 200-day moving average is $205.13.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.